Following a registration submission, shares of Accuray Incorporated (Nasdaq: ARAY) were up 4.00% at $2.08 at the time of our last check in after-hours trading.
What kind of registration did ARAY submit?
The Chinese National Medical Products Administration (NMPA) has received the registration dossier for the CNNC-Accuray joint venture Tomo C radiation treatment system for the Type B market, according to Accuray (ARAY). During the company’s Q4 FY2022 earnings conference, Accuray provided a schedule that this milestone fits inside. The NMPA must examine and provide its permission before Tomo C is made available. The first joint venture product is a novel manufactured in China system that was created expressly to increase access to precision radiation treatments for more cancer patients in China.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Between 2020 and 20401, it is predicted that there will be a roughly 50% rise in the number of new cancer cases identified in China, with increases in the incidence of not just lung cancer but also colorectal, breast, and prostate cancers2. One of the main forms of treatment for lung, breast, and prostate cancers is radiation therapy, which emphasizes the need for novel strategies that successfully treat the illness while reducing the likelihood of adverse effects and their negative consequences on quality of life.
The filing of the Tomo C dossier is a critical milestone for the joint venture between CNNC and Acuray and serves as a key growth accelerator for ARAY. The technology will greatly improve the joint venture’s product range and competitiveness in the future in the sizable and quickly expanding Type B category. More individuals in China will be able to access the treatment that is crucial to their long-term health thanks to the team’s emphasis on ensuring ARAY has the correct solutions to satisfy the demands of the Chinese radiation therapy market, which is the fastest-growing in the world.
The TomoTherapy platform is the first in the world to be able to integrate helical fan-beam imaging and radiation delivery. This enables the delivery of conventionally fractionated to ultra-hypofractionated treatments while allowing for greater control of the radiation dose and better normal tissue preservation. The system is capable of treating all indications for radiation therapy that are generally accepted, including malignancies of the breast, prostate, lung, abdomen, and head and neck, as well as more complicated procedures such as complete marrow irradiation.
How is ARAY changing things?
This submittal and the creation of a TomoTherapy platform device built in-country demonstrate Accuray (ARAY) dedication to the joint venture. The majority of Chinese consumers who seek a quick and efficient radiation delivery system will probably be satisfied by Tomo C. Chinese clients will be able to provide extremely accurate radiation therapy to more patients every day thanks to the first equipment produced in China.
